SAN ANTONIO, Nov. 7, 2007 (PRIME NEWSWIRE) -- Sweet Success Enterprises (OTCBB:SWTS), the maker of GlucaSafe(tm) which supports healthy glucose levels and a line of innovative and delicious healthy-lifestyle beverages, today announced that its revolutionary beverage, GlucaSafe(tm), receives early results on the current GlucaSafe(tm) clinical trial being held to determine healthy glucose levels and long-term blood sugar control as evidenced by Hgb A1C measurements.
The GlucaSafe(tm) clinical trial is being conducted in Atlanta, Georgia, by Howard A. Reisman, MD, a veteran Clinical Trial Investigator with 15 years of Clinical Trial experience who has conducted more than 75 Clinical Trials for the Pharmaceutical Industry. Dr. Reisman has conducted more than 75 clinical trials to-date, including an insomnia treatment study for Upjohn Pharmaceuticals. He received his medical degree in 1978 from the Medical College of Georgia.
Dr. Reisman noted that, "At this time, seven patients are enrolled in a 12-week, open-labeled trial monitoring serum glucose levels and Hemoglobin A1C levels for Type II Diabetes. The patients consume two servings of GlucaSafe(tm) daily. Interim trial results demonstrate a reduction in serum Glucose ranging from 20% to 40% from baseline levels in trial participants. Only one patient has been in the trial long enough to test an Hgb A1C level after 12 weeks of the trial. This particular patient had a 7.4 Hgb A1C upon enrollment, and after 12 weeks of the trial it has dropped to 7.0. There appears to be a trend where we are seeing patients with higher serum glucose levels upon enrollment experience a reduction in their serum glucose after consuming GlucaSafe(tm)."
GlucaSafe(tm) ingredients have undergone substantial clinical trials for their ingredients which include Green Tea, White Tea and Pomegranate extract which serve as an antioxidant promoting overall health and immunity; Cinnamon extract, shown by the USDA to help stabilize glucose levels; Banaba Leaf, a glucose stabilizer that controls appetite, food cravings and, accordingly, promotes weight loss; Chromium Polynicotinate promotes the regulation and maintenance of normal cholesterol levels and supports the metabolism of fats and sugars; and Stevioside has been shown to reduce high blood sugar, lower blood pressure and is considered an alternative supplementary therapy for hypertension.
Product statements have not been evaluated by the FDA. The products are not intended to diagnose, treat, cure or prevent disease.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements which address actual results could differ materially from those expressed or implied in forward-looking statements. These statements are made on the basis of management's views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that the ability to attract clients and generate business may be affected by a decline in the Company's financial ratings, the competitive environment, the Company's ability to raise sufficient capital to meet the collateral requirements associated with its current business and to fund the Company's continuing operations and changes in market conditions.